FTC Ends Probe Into Allergan’s Practices
From Bloomberg News
Allergan Inc., the maker of Botox anti-wrinkle treatments, said the Federal Trade Commission had closed its investigation into whether the company hindered generic drug makers from making copies of its Acular eye drug.
Irvine-based Allergan said the decision followed a U.S. District Court ruling in December that concluded the patent covering Acular was valid and enforceable, the company said.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
